1799 Stock Overview
Develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in the United States and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Easywell Biomedicals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$73.00 |
| 52 Week High | NT$233.00 |
| 52 Week Low | NT$38.00 |
| Beta | 0.60 |
| 11 Month Change | -28.78% |
| 3 Month Change | -68.12% |
| 1 Year Change | 79.80% |
| 33 Year Change | 219.38% |
| 5 Year Change | 428.44% |
| Change since IPO | 62.21% |
Recent News & Updates
Shareholder Returns
| 1799 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | 10.6% | 0.5% | 0.8% |
| 1Y | 79.8% | 0.7% | 30.3% |
Return vs Industry: 1799 exceeded the TW Medical Equipment industry which returned 0.7% over the past year.
Return vs Market: 1799 exceeded the TW Market which returned 30.3% over the past year.
Price Volatility
| 1799 volatility | |
|---|---|
| 1799 Average Weekly Movement | 11.3% |
| Medical Equipment Industry Average Movement | 3.9% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 1799's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 1799's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | James Aiping Lee | www.easywellbio.com |
Easywell Biomedicals, Inc. develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in the United States and Asia. It develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angina; and TLX-011 for treatment of inflammatory lesions of rosacea. The company also develops TWB-201 for Parkinson patch; TLX-501, an urinary medicine; and TLX-502, a pneumonia medicine, as well as provides medical devices.
Easywell Biomedicals, Inc. Fundamentals Summary
| 1799 fundamental statistics | |
|---|---|
| Market cap | NT$8.90b |
| Earnings (TTM) | -NT$141.45m |
| Revenue (TTM) | NT$361.49m |
24.6x
P/S Ratio-62.9x
P/E RatioIs 1799 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1799 income statement (TTM) | |
|---|---|
| Revenue | NT$361.49m |
| Cost of Revenue | NT$131.35m |
| Gross Profit | NT$230.14m |
| Other Expenses | NT$371.60m |
| Earnings | -NT$141.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.16 |
| Gross Margin | 63.66% |
| Net Profit Margin | -39.13% |
| Debt/Equity Ratio | 6.0% |
How did 1799 perform over the long term?
See historical performance and comparison